Phase I trial

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. […]

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2.   Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.  Trop2 (Trophoblast cell-surface antigens 2), […]

The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR).   The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities. This includes research into cancer and heart […]

A Phase I safety and pharmacodynamic activity trial shows IMC-M113V, the first soluble T cell receptor (TCR) therapy for people living with HIV, is well tolerated.  Immunocore presented the findings at the Conference on Retroviruses and Opportunistic Infection (CROI).  The bispecific soluble TCR therapy built on the company’s ImmTAX technology which is being developed for […]

Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke.  The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose.   The study results were presented at the American Heart Association International Stroke Conference (ISC) 2023 in Dallas, […]

The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test.  The approval is for endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting […]

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial.  In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling […]

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023 with the final report in June 2023.   The […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good […]

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine […]